Evidence map›Paper›PMID 31888483›Full record

ArticleBMC microbiology2019

Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity.

Madina Kozhieva, Natalia Naumova, Tatiana Alikina, Alexey Boyko, Valentin Vlassov, Marsel R Kabilov

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 5 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023
    Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Lysate ofFrontiers in immunology · 2024
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Madina KozhievaDepartment of Neurology, Neurosurgery and Medical Genetics of the Pirogov Medical University, Ostrovitianova 1, 117513, Moscow, Russia.
Natalia NaumovaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev 8, Novosibirsk, 630090, Russia. nnaumova@mail.ru.ORCID 0000-0003-2354-5065
Tatiana AlikinaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev 8, Novosibirsk, 630090, Russia.
Alexey BoykoDepartment of Neurology, Neurosurgery and Medical Genetics of the Pirogov Medical University, Ostrovitianova 1, 117513, Moscow, Russia.
Valentin VlassovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev 8, Novosibirsk, 630090, Russia.
Marsel R KabilovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentiev 8, Novosibirsk, 630090, Russia.
Institute of Chemical Biology and Fundamental Medicine · RUPirogov Russian National Research Medical University · RU

Funding

Ministry of Science and Higher Education, Russia АААА-А17-117020210021-7Russian Foundation for Basic Research 17-00-00206Russian Foundation for Basic Research 17-00-00210Russian Foundation for Basic Research 17-00-00295
6 · The paper itself

Abstract

backgroundGut microbiota has been increasingly acknowledged to shape significantly human health, contributing to various autoimmune diseases, both intestinal and non-intestinal, including multiple sclerosis (MS). Gut microbiota studies in patients with relapsing remitting MS strongly suggested its possible role in immunoregulation; however, the profile and potential of gut microbiota involvement in patients with primary progressive MS (PPMS) patients has received much less attention due to the rarity of this disease form. We compared the composition and structure of faecal bacterial assemblage using Illumina MiSeq sequencing of V3-V4 hypervariable region of 16S rRNA genes amplicons in patients with primary progressive MS and in the healthy controls.

resultsOver all samples 12 bacterial phyla were identified, containing 21 classes, 25 orders, 54 families, 174 genera and 1256 operational taxonomic units (OTUs). The Firmicutes phylum was found to be ultimately dominating both in OTUs richness (68% of the total bacterial OTU number) and in abundance (71% of the total number of sequence reads), followed by Bacteroidetes (12 and 16%, resp.) and Actinobacteria (7 and 6%, resp.). Summarily in all samples the number of dominant OTUs, i.e. OTUs with ≥1% relative abundance, was 13, representing much less taxonomic richness (three phyla, three classes, four orders, six families and twelve genera) as compared to the total list of identified OTUs and accounting for 30% of the sequence reads number in the healthy cohort and for 23% in the PPMS cohort. Human faecal bacterial diversity profiles were found to differ between PPMS and healthy cohorts at different taxonomic levels in minor or rare taxa. Marked PPMS-associated increase was found in the relative abundance of two dominant OTUs (Gemmiger sp. and an unclassified Ruminococcaceae). The MS-related differences were also found at the level of minor and rare OTUs (101 OTUs). These changes in OTUs' abundance translated into increased bacterial assemblage diversity in patients.

conclusionThe findings are important for constructing a more detailed global picture of the primary progressive MS-associated gut microbiota, contributing to better understanding of the disease pathogenesis.

Indexed as

Gastrointestinal MicrobiomeGenetic VariationAdultAgedBacteriaCase-Control StudiesDNA, BacterialFecesFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMultiple Sclerosis, Chronic ProgressivePhylogenyRNA, Ribosomal, 16SDNA, BacterialRNA, Ribosomal, 16S16S rRNA gene amplicon sequencingFaecal bacterial assemblageHumansMultiple sclerosisPrimary progressive course

Identifiers

PMID31888483
PMCPMC6937728
OpenAlexW2997679194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.